Updated on 19 September 2016
South Korea boasts the second highest number of approved clinical trial sites
Singapore: With a view to address the growing demand in clinical services, Thermo Fisher Scientific has opened a new clinical services facility in South Korea. Located in Seoul, the new site will provide local, regional and global pharmaceutical and biotech companies with a one-stop service for clinical supplies - from cGMP storage, local labelling, secondary packaging, comparator sourcing, handling and distribution of ambient and cold chain supplies to clinical site returns management.
Korea is gaining traction as a one of the top destination for clinical trials, thanks to its supportive government, modern infrastructure and an easily accessible patient population. Over the past few years, clinical trials have consistently grown in South Korea, and with an increased number of core clinical trial sites certified by the Ministry of Food and Drug Safety (MFDS).
South Korea boasts the second highest number of approved clinical trial sites globally, making it a leading emerging nation for clinical trial research in Asia. In addition, South Korean R&D pharmaceutical companies have demonstrated a strong passion for innovative drug development resulting in a robust industry contributing to therapeutic healthcare developments at local and global levels.
"Thermo Fisher Scientific was established in South Korea in 1994, and over the past 22 years our goal has been to invest in local infrastructure and presence to better support the market specific needs of our customers," said Tony Acciarito, vice president and general manager of Thermo Fisher South Korea. "Now, with over 430 employees across the organization, the new facility represents another step towards this goal which is aligned to our company Mission to enable our customers to make the world healthier, cleaner and safer."
Speaking about this facility, Mr Leon Wyszkowski, Thermo Fisher's vice president of clinical services for North America and facility network, said, ""Asia Pacific continues to be our fastest-growing market and a central contributor to our growth. In September 2015, we opened a new facility in Singapore to serve as a central hub for our Asia Pacific region, which complements our clinical services facilities in Beijing and Suzhou (China); Tokyo (Japan) and Ahmedabad (India). The opening of this new facility in South Korea is testament to our commitment to continue investing in the region as we build on the expertise of our local teams to strengthen our regional and global presence in the clinical supplies industry."
Thermo Fisher Scientific is the world leader in serving science, with revenues of $17 billion and more than 50,000 employees in 50 countries. The company enabling biotech and pharmaceutical companies accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity, through their premier brands - Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services.